Cargando…

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia

BACKGROUND: Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Extramedullary (EM) relapse after TMLI is comparable to TBI a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladbury, Colton, Semwal, Hemal, Hong, Daniel, Yang, Dongyun, Hao, Claire, Han, Chunhui, Liu, An, Marcucci, Guido, Rosenthal, Joseph, Hui, Susanta, Salhotra, Amandeep, Ali, Haris, Nakamura, Ryotaro, Stein, Anthony, Al Malki, Monzr, Wong, Jeffrey Y. C., Dandapani, Savita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660291/
https://www.ncbi.nlm.nih.gov/pubmed/36387179
http://dx.doi.org/10.3389/fonc.2022.1017355
_version_ 1784830390048915456
author Ladbury, Colton
Semwal, Hemal
Hong, Daniel
Yang, Dongyun
Hao, Claire
Han, Chunhui
Liu, An
Marcucci, Guido
Rosenthal, Joseph
Hui, Susanta
Salhotra, Amandeep
Ali, Haris
Nakamura, Ryotaro
Stein, Anthony
Al Malki, Monzr
Wong, Jeffrey Y. C.
Dandapani, Savita
author_facet Ladbury, Colton
Semwal, Hemal
Hong, Daniel
Yang, Dongyun
Hao, Claire
Han, Chunhui
Liu, An
Marcucci, Guido
Rosenthal, Joseph
Hui, Susanta
Salhotra, Amandeep
Ali, Haris
Nakamura, Ryotaro
Stein, Anthony
Al Malki, Monzr
Wong, Jeffrey Y. C.
Dandapani, Savita
author_sort Ladbury, Colton
collection PubMed
description BACKGROUND: Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Extramedullary (EM) relapse after TMLI is comparable to TBI and non-TBI conditioning regimens. This study evaluates outcomes of patients treated with radiotherapy (RT) with EM relapse previously treated with TMLI. METHODS: A retrospective analysis of five prospective TMLI trials was performed. TMLI targeted bones and major lymphoid tissues using image-guided tomotherapy, with total dose ranging from 12 to 20 Gy. EM recurrences were treated at the discretion of the hematologist and radiation oncologist using RT ± chemotherapy. Descriptive statistics and survival analysis were then performed on this cohort. RESULTS: In total, 254 patients with refractory or relapsed AML or ALL were treated with TMLI at our institution. Twenty-one patients were identified as receiving at least one subsequent course of radiation. A total of 67 relapse sites (median=2 sites/patient, range=1-16) were treated. Eleven relapsed patients were initially treated with curative intent. Following the initial course of subsequent RT, 1-year, 3-year and 5-year estimates of OS were 47.6%, 32.7% and 16.3%, respectively. OS was significantly better in patients treated with curative intent, with median OS of 50.7 months vs 1.6 months (p<0.001). 1-year, 3-year and 5-year estimates of PFS were 23.8%, 14.3% and 14.3%, respectively. PFS was significantly better in patients treated with curative intent, with median PFS of 6.6 months vs 1.3 months (p<0.001). Following RT, 86.6% of the sites had durable local control. CONCLUSIONS: RT is an effective modality to treat EM relapse in patients with acute leukemia who relapse after HCT achieving high levels of local control. In patients with limited relapse amenable to curative intent, radiation confers favorable long-term survival. Radiation as salvage treatment for EM relapse after HCT warrants further evaluation.
format Online
Article
Text
id pubmed-9660291
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96602912022-11-15 Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia Ladbury, Colton Semwal, Hemal Hong, Daniel Yang, Dongyun Hao, Claire Han, Chunhui Liu, An Marcucci, Guido Rosenthal, Joseph Hui, Susanta Salhotra, Amandeep Ali, Haris Nakamura, Ryotaro Stein, Anthony Al Malki, Monzr Wong, Jeffrey Y. C. Dandapani, Savita Front Oncol Oncology BACKGROUND: Total Marrow and Lymphoid Irradiation (TMLI) is a promising component of the preparative regimen for hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Extramedullary (EM) relapse after TMLI is comparable to TBI and non-TBI conditioning regimens. This study evaluates outcomes of patients treated with radiotherapy (RT) with EM relapse previously treated with TMLI. METHODS: A retrospective analysis of five prospective TMLI trials was performed. TMLI targeted bones and major lymphoid tissues using image-guided tomotherapy, with total dose ranging from 12 to 20 Gy. EM recurrences were treated at the discretion of the hematologist and radiation oncologist using RT ± chemotherapy. Descriptive statistics and survival analysis were then performed on this cohort. RESULTS: In total, 254 patients with refractory or relapsed AML or ALL were treated with TMLI at our institution. Twenty-one patients were identified as receiving at least one subsequent course of radiation. A total of 67 relapse sites (median=2 sites/patient, range=1-16) were treated. Eleven relapsed patients were initially treated with curative intent. Following the initial course of subsequent RT, 1-year, 3-year and 5-year estimates of OS were 47.6%, 32.7% and 16.3%, respectively. OS was significantly better in patients treated with curative intent, with median OS of 50.7 months vs 1.6 months (p<0.001). 1-year, 3-year and 5-year estimates of PFS were 23.8%, 14.3% and 14.3%, respectively. PFS was significantly better in patients treated with curative intent, with median PFS of 6.6 months vs 1.3 months (p<0.001). Following RT, 86.6% of the sites had durable local control. CONCLUSIONS: RT is an effective modality to treat EM relapse in patients with acute leukemia who relapse after HCT achieving high levels of local control. In patients with limited relapse amenable to curative intent, radiation confers favorable long-term survival. Radiation as salvage treatment for EM relapse after HCT warrants further evaluation. Frontiers Media S.A. 2022-10-31 /pmc/articles/PMC9660291/ /pubmed/36387179 http://dx.doi.org/10.3389/fonc.2022.1017355 Text en Copyright © 2022 Ladbury, Semwal, Hong, Yang, Hao, Han, Liu, Marcucci, Rosenthal, Hui, Salhotra, Ali, Nakamura, Stein, Al Malki, Wong and Dandapani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ladbury, Colton
Semwal, Hemal
Hong, Daniel
Yang, Dongyun
Hao, Claire
Han, Chunhui
Liu, An
Marcucci, Guido
Rosenthal, Joseph
Hui, Susanta
Salhotra, Amandeep
Ali, Haris
Nakamura, Ryotaro
Stein, Anthony
Al Malki, Monzr
Wong, Jeffrey Y. C.
Dandapani, Savita
Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
title Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
title_full Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
title_fullStr Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
title_full_unstemmed Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
title_short Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
title_sort role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660291/
https://www.ncbi.nlm.nih.gov/pubmed/36387179
http://dx.doi.org/10.3389/fonc.2022.1017355
work_keys_str_mv AT ladburycolton roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT semwalhemal roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT hongdaniel roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT yangdongyun roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT haoclaire roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT hanchunhui roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT liuan roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT marcucciguido roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT rosenthaljoseph roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT huisusanta roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT salhotraamandeep roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT aliharis roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT nakamuraryotaro roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT steinanthony roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT almalkimonzr roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT wongjeffreyyc roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia
AT dandapanisavita roleofradiotherapyintreatmentofextramedullaryrelapsefollowingtotalmarrowandlymphoidirradiationinhighriskandorrelapsedrefractoryacuteleukemia